Melphalan Tillomed

Melphalan, the active ingredient in Melphalan Tillomed, is an alkylating agent presented as an intravenous formulation for intravenous use. It is employed in the treatment of certain cancers such as multiple myeloma, ovarian cancer and melanoma in adult patients.

GNH USA supplies Melphalan Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Melphalan Tillomed is an alkylating antineoplastic agent used in chemotherapy regimens for hematologic and solid tumours.

Multiple myeloma: helps achieve disease control as part of induction or conditioning protocols. Ovarian cancer: used in combination regimens to reduce tumour burden and improve response rates. Melanoma: applied in high‑dose schedules for metastatic disease to prolong survival.

Melphalan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Myelosuppression (neutropenia, anemia, thrombocytopenia) - Alopecia (hair loss) - Fatigue and weakness - Mucositis or oral ulceration - Diarrhoea

Serious or Rare Side Effects: - Secondary malignancies (e.g., acute leukaemia) - Severe neutropenic infections - Hemorrhagic cystitis - Pulmonary toxicity (interstitial pneumonitis) - Renal impairment or failure - Anaphylactic or severe allergic reactions

When using Melphalan, clinicians should observe several safety measures.

Monitor blood counts: perform regular CBC to detect myelosuppression. Assess renal function: adjust therapy if creatinine clearance is reduced. Evaluate hepatic function: consider dose modification in liver impairment. Avoid in patients with known hypersensitivity to melphalan or related compounds. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Melphalan can interact with other medicines, influencing efficacy or toxicity.

Major Interactions (Avoid): - Concomitant use with other alkylating agents (e.g., cyclophosphamide) may increase myelotoxicity. - Live vaccines: risk of infection due to immunosuppression. - High‑dose radiation therapy: additive tissue damage.

Moderate Interactions (Monitor Closely): - Antiemetics (e.g., ondansetron) may require dose adjustment for optimal control of nausea. - Granulocyte‑colony stimulating factors (G‑CSF) to mitigate neutropenia. - NSAIDs: may exacerbate renal toxicity. - Anticoagulants: monitor for bleeding if thrombocytopenia occurs. - CYP450 inducers (e.g., rifampicin) could reduce plasma levels.